Roivant Sciences Ltd.
Close on Nov 18, 2026Market cap $27.98BP/E –Yield –
Roivant Sciences Priovant Therapeutics — Basic Ownership Stake by Quarter
Priovant Therapeutics — Basic Ownership Stake (%)
Roivant Sciences Priovant Therapeutics — Basic Ownership Stake: 71.0% in Q2 FY2026, down 2.0 pts from a year earlier. That is the lowest of the 15 quarters on record here.
Where the Q2 FY2026 figure comes from
“|| Priovant | 71 | % | 65 | %”
Source: Form 10-Q (roiv-20260930.htm, filed 2026-11-09) ↗
Joint venture formed with Pfizer Inc. developing LISRAYA (brepocitinib).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up priovant Therapeutics — Basic Ownership Stake
Cite this data
StockData. (2026). Roivant Sciences Priovant Therapeutics — Basic Ownership Stake (%), quarterly Q4 FY2021–Q2 FY2026 [Data set]. Compiled from Roivant Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/roiv/kpis/own-priovant-basic
See every metric in the Roivant Sciences KPI table. Data updated Nov 16, 2026.
See a number that looks wrong?